[go: up one dir, main page]

PE20151722A1 - Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral - Google Patents

Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral

Info

Publication number
PE20151722A1
PE20151722A1 PE2015001253A PE2015001253A PE20151722A1 PE 20151722 A1 PE20151722 A1 PE 20151722A1 PE 2015001253 A PE2015001253 A PE 2015001253A PE 2015001253 A PE2015001253 A PE 2015001253A PE 20151722 A1 PE20151722 A1 PE 20151722A1
Authority
PE
Peru
Prior art keywords
prevention
treatment
viral disease
improvement
pyrimidone derivatives
Prior art date
Application number
PE2015001253A
Other languages
English (en)
Inventor
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Helmut Buschmann
Stephen Cusack
Mark Smith
Sung-Sau So
Ronald Charles Hawley
Achyutharao Sidduri
Zhuming Zhang
Original Assignee
European Molecular Biology Lab Embl
Hoffmann La Roche
Savira Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151722(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by European Molecular Biology Lab Embl, Hoffmann La Roche, Savira Pharmaceuticals Gmbh filed Critical European Molecular Biology Lab Embl
Publication of PE20151722A1 publication Critical patent/PE20151722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere al desarrollo de derivados de 3,4-dihidro-2H-pirazino[1,2-c]pirimidina-1,8-diona de formula (I), opcionalmente en la forma de una sal, solvato, polimorfo, profarmaco, cofarmaco, cocristal, tautomero, racemato, enantiomero o diastereomero farmaceuticamente aceptable o sus mezclas, que son utiles en el tratamiento, la mejora o prevencion de una enfermedad viral. Ademas, se describen tratamientos de combinacion especificos
PE2015001253A 2013-01-08 2014-01-07 Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral PE20151722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08

Publications (1)

Publication Number Publication Date
PE20151722A1 true PE20151722A1 (es) 2015-11-19

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001253A PE20151722A1 (es) 2013-01-08 2014-01-07 Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral

Country Status (21)

Country Link
US (1) US9045486B2 (es)
EP (1) EP2943495B1 (es)
JP (1) JP2016518305A (es)
KR (1) KR20150103285A (es)
CN (1) CN104918942A (es)
AR (1) AR094378A1 (es)
AU (1) AU2014204889A1 (es)
BR (1) BR112015012693A2 (es)
CA (1) CA2894642A1 (es)
CL (1) CL2015001916A1 (es)
CR (1) CR20150337A (es)
EA (1) EA201591291A1 (es)
HK (1) HK1211286A1 (es)
IL (1) IL239656A0 (es)
MA (1) MA38323B1 (es)
MX (1) MX2015008293A (es)
PE (1) PE20151722A1 (es)
PH (1) PH12015501517A1 (es)
SG (1) SG11201503946UA (es)
TW (1) TW201443053A (es)
WO (1) WO2014108406A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
AU2016256125B9 (en) 2015-04-28 2020-02-20 Shionogi And Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
PL3290424T3 (pl) 2015-04-28 2023-05-08 Shionogi & Co., Ltd Podstawione policykliczne pochodne pirydonu i ich prolek
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
CR20180356A (es) 2015-12-15 2018-08-22 Shionogi & Co Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US10858366B2 (en) * 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
JP6957518B2 (ja) * 2016-05-20 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物
HRP20201131T1 (hr) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
KR20190007517A (ko) 2016-08-10 2019-01-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US11629149B2 (en) 2018-02-28 2023-04-18 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021195278A1 (en) * 2020-03-25 2021-09-30 Webb Thomas R Tricyclic inhibitors of influenza virus endonuclease
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof
KR20250086780A (ko) 2022-10-19 2025-06-13 아스트라제네카 아베 Cx3cr1 조절제로서의 2,4,6-삼중치환된 1,3,5-트리아진

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
CA2557926A1 (en) * 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
CA2616314A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
HRP20181250T1 (hr) 2010-09-24 2018-10-05 Shionogi & Co., Ltd. Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona

Also Published As

Publication number Publication date
AR094378A1 (es) 2015-07-29
TW201443053A (zh) 2014-11-16
JP2016518305A (ja) 2016-06-23
KR20150103285A (ko) 2015-09-09
WO2014108406A1 (en) 2014-07-17
CA2894642A1 (en) 2014-07-17
CR20150337A (es) 2015-11-02
IL239656A0 (en) 2015-08-31
AU2014204889A1 (en) 2015-06-11
EP2943495B1 (en) 2016-12-28
CL2015001916A1 (es) 2016-01-22
BR112015012693A2 (pt) 2017-07-11
PH12015501517A1 (en) 2015-11-09
US9045486B2 (en) 2015-06-02
SG11201503946UA (en) 2015-09-29
HK1211286A1 (en) 2016-05-20
MA38323A1 (fr) 2017-02-28
HK1212686A1 (en) 2016-06-17
MX2015008293A (es) 2016-06-02
CN104918942A (zh) 2015-09-16
US20140194431A1 (en) 2014-07-10
EP2943495A1 (en) 2015-11-18
EA201591291A1 (ru) 2015-12-30
MA38323B1 (fr) 2018-05-31

Similar Documents

Publication Publication Date Title
PE20151722A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2018007815A (es) Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma.
BR112014029006A2 (pt) derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX342176B (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
CU20170007A7 (es) Compuestos de imidazopiridazina
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
CL2017002651A1 (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos

Legal Events

Date Code Title Description
FD Application declared void or lapsed